Research presented by bioAffinity Technologies demonstrates the potential of small interfering RNAs (siRNAs) targeting the CD320 and LRP2 receptors as a treatment approach for cutaneous squamous and basal cell carcinomas. In preliminary laboratory studies, self-delivering, stabilized siRNAs targeting CD320 and LRP2 demonstrated toxicity against squamous and basal cell carcinoma cells while largely preserving the viability of noncancerous skin cells. The stabilized siRNAs also demonstrated the ability to enter skin cancer cells, supporting their potential for topical therapeutic development. Further research is underway to optimize dosing regimens and advance this investigational approach to treating skin cancer.